Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
neck swelling, persistent hoarseness, or difficulty swallowing
Back to Journals Drug, Healthcare and Patient Safety Volume 18 Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method Authors Gu S Received 29 July 2025 Accepted for publication 3 January 2026 Published 8 January 2026 Volume 2026:18 556918 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Siew Siang Chua Saisai Gu Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Peoples Republic of China Correspondence: Saisai Gu, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Peoples Republic of China, Email [email protected] Purpose: Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals
Hormone Disruption by PBDEs in Adult Male Sport Fish Consumers
Pressure within the appendix will increase, limiting the amount of blood flowing through the walls of the appendix, where the tissue then becomes starved of blood and starts to die
